Eli Lilly and Co. has won federal approval to market its hot-selling anti-inflammatory drug Taltz for another use: treatment of a type of arthritis that does not show any structural body damage on ...
Eli Lilly's Taltz and Novartis' Cosentyx have been jockeying for IL-17 inhibitor supremacy with back-and-forth FDA approvals for years. But in the race for a fourth indication, Taltz has come out on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback